Enthera is an Italian biotech start-up building a pipeline of first-in-class biologics for several underserved autoimmune conditions, with a focus on Type 1 Diabetes (T1D) and Inflammatory Bowel Disease (IBD).

Enthera was founded by BiovelocITA in October 2016 in collaboration with the scientists Prof. Paolo Fiorina and Dr. Francesca D’Addio, with the mission to find new therapeutic approaches to treat diabetes, related gastrointestinal complication (enteropathy) and intestinal disorders with the same biological pathway. Since its foundation, the company has collected important scientific achievements and raised several rounds with the participation of international VCs and strategic players.

Atlante Seed invested in the company in 2018.